ArticleFrontiers in oncology2026
Molecular characteristics and
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gastric cancer incidence and characteristics vary due to environmental factors, and technical advances facilitate early detection of the disease. This study aimed to assess whether significant socio-economic changes and technological advancements in Poland - one of the most rapidly developing countries worldwide - affected the molecular characteristics and detection rates of early gastric cancer sub-types in Western Poland. Methods: Ninety-two patients undergoing gastrectomy for gastric cancer in 1998-2002 and 2016-2020 were studied. Surgical specimens were re-analyzed for histopathological features, including tumor type, grade, and stage (up-dated World Health Organization [WHO] classification). Immunohistochemical markers (Ki-67, p53, E-cadherin, CD10, CD31, bcl-2) and antigens for Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV) were evaluated. Microsatellite instability (MSI) was assessed via PMS2/MSH2 protein expression. Results: The groups were comparable in age and gender, with male predominance. Histological features, H. pylori and EBV colonization, and most molecular markers showed no significant differences. However, Ki-67 proliferation index significantly increased in cancers diagnosed in 2016-2020, correlating with intestinal-type tumors and p53 expression. In this group, higher Ki-67 levels were also linked to H. pylori infection, microsatellite stability, and increased angiogenesis. Conclusions: Despite advancements in H. pylori research and technology over 20 years, no improvement was observed in H. pylori-positive tumor rates or early gastric cancer detection in Western Poland. Although molecular characteristics remained largely unchanged, the increased proliferation index in recently diagnosed cancers merits further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.